Finding patients at risk for a germline mutation in the p16 gene and following up with them is perhaps the most critical step in potentially changing hereditary cancer outcomes. The following Indicators* in a patient’s personal or family history are suggestive of the presence of a p16 mutation. Indicators identify patients at risk for a p16 mutation, for whom further clinical evaluation to determine appropriateness of genetic testing is warranted.
- Two or more melanomas in an individual or family
- Melanoma and pancreatic cancer in an individual or family
- Relatives of a p16 mutation carrier
* Assessment criteria based on scientific literature and expert opinion. For a list of references, go to references.